Compare American Water Works Company Inc (AWK) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Cytokinetics Inc — how do they compare? American Water Works Company Inc trades at $134.45 (market cap $26.92B), while Cytokinetics Inc trades at $77.95 (market cap $10.78B). The key difference: American Water Works Company Inc is far larger — about 2.5× Cytokinetics Inc's market cap, and American Water Works Company Inc pays a 2.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AWK | CYTK | |
|---|---|---|
Market Cap | $26.92B | $10.78B |
Sector | Utilities | Technology |
52-Week High | $146.20 | $87.26 |
52-Week Low | $121.13 | $33.23 |
Enterprise Value | $42.78B | $10.88B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AWK trades at $135.31, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.61, beating estimates, while Q1 and Q4 2025 missed. Revenue grew to $5.14B in 2025 with a 21.35% net margin. Analyst consensus is mixed with 14 Buy, 14 Hold, and 2 Sell ratings, targeting $139.83. Recent news highlights operational excellence awards and customer base expansion through acquisitions.
Outlook remains stable with consistent dividend payments and guided EPS growth. Risks include rising debt levels and regulatory pressures. The stock offers steady income and moderate growth potential, but investors should monitor execution on earnings targets and capital expenditure efficiency.
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
